Evidence map›Paper›PMID 29473879›Full record

ArticleMolecules (Basel, Switzerland)2018

In Silico-Based Repositioning of Phosphinothricin as a Novel Technetium-99m Imaging Probe with Potential Anti-Cancer Activity.

Tamer M Sakr, Mohammed A Khedr, Hassan M Rashed, Maged E Mohamed

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Frontiers in pharmacology · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Tamer M SakrRadioactive Isotopes and Generator Department, Hot Labs Center, Atomic Energy Authority, Cairo 13759, Egypt. tamer_sakr78@yahoo.com.ORCID 0000-0001-9162-5687
Mohammed A KhedrDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Ein Helwan, Cairo 11795, Egypt. mohammed_abdou0@yahoo.com.
Hassan M RashedLabeled Compounds Department, Hot Labs Center, Atomic Energy Authority, Cairo 13759, Egypt. H_rashed@yahoo.com.
Maged E MohamedCollege of Clinical Pharmacy, King Faisal University, Al-Hasaa 31982, Kingdom of Saudi Arabia. maged789@hotmail.com.ORCID 0000-0002-1216-8703
Egyptian Atomic Energy Authority · EGKing Faisal University · SAZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

l-Phosphinothricin (glufosinate or 2-amino-4-((hydroxy(methyl) phosphinyl) butyric acid ammonium salt (AHPB)), which is a structural analog of glutamate, is a recognized herbicide that acts on weeds through inhibition of glutamine synthetase. Due to the structural similarity between phosphinothricin and some bisphosphonates (BPs), this study focuses on investigating the possibility of repurposing phosphinothricin as a bisphosphonate analogue, particularly in two medicine-related activities: image probing and as an anti-cancer drug. As BP is a competitive inhibitor of human farnesyl pyrophosphate synthase (HFPPS), in silico molecular docking and dynamic simulations studies were established to evaluate the binding and stability of phosphinothricin with HFPPS, while the results showed good binding and stability in the active site of the enzyme in relation to alendronate. For the purpose of inspecting bone-tissue accumulation of phosphinothricin, a technetium (

Indexed as

Drug RepositioningAlendronateAminobutyratesAnimalsAntineoplastic AgentsBinding SitesCell Line, TumorCell ProliferationDiagnostic ImagingDrug StabilityHumansHydrogen-Ion ConcentrationMiceMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureAlendronateAminobutyratesAntineoplastic AgentsphosphinothricinRadiopharmaceuticalsTechnetiumTechnetium-99cancer imagingin-silicomolecular dockingphosphinothricinrepositioningtechnetium-99m

Identifiers

PMID29473879
PMCPMC6017358
OpenAlexW2792051010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.